To hear about similar clinical trials, please enter your email below
Trial Title:
Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors
NCT ID:
NCT05628077
Condition:
Breast Cancer
Aromatase Inhibitors
Endocrine Therapy
Pain
Anxiety
Depression
Sleep
Conditions: Official terms:
Breast Neoplasms
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Other
Intervention name:
No intervention
Description:
No intervention
Arm group label:
NO PAIN
Arm group label:
PAIN
Summary:
We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine
therapy in breast cancer patients through telephone follow-up, and analyzed risk factors
through artificial intelligence
Criteria for eligibility:
Study pop:
I-III Breast cancer survivors on aromatase inhibitors
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Breast cancer survivors on aromatase inhibitors
Exclusion Criteria:
- Advanced breast cancer
Gender:
Female
Minimum age:
18 Years
Maximum age:
90 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Peking University People'S Hospital
Address:
City:
Beijing
Zip:
000000
Country:
China
Status:
Recruiting
Contact:
Last name:
Huifang Li
Phone:
18538078485
Email:
lihuifang19910318@outlook.com
Start date:
December 30, 2022
Completion date:
April 20, 2023
Lead sponsor:
Agency:
Peking University People's Hospital
Agency class:
Other
Source:
Peking University People's Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05628077
